A difference in opinion apparently prompted the FDA to issue Guilford Pharmaceuticals Inc. a non-approvable letter rejecting a supplemental new drug application for use of the Gliadel Wafer in patients with newly diagnosed malignant glioma. (BioWorld Today) Read More
